Add-back

DRUG2 trials

Sponsors

ObsEva SA

Conditions

Heavy Menstrual BleedingUterine Fibroids

Phase 3

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

CompletedNCT03070899

ObsEva SAHeavy Menstrual Bleeding, Uterine Fibroids

Start: 2017-04-20End: 2021-04-12Updated: 2021-06-09

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

CompletedNCT03070951

ObsEva SAHeavy Menstrual Bleeding, Uterine Fibroids

Start: 2017-05-23End: 2020-10-04Updated: 2021-03-05

Related Papers

Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study

Fertility and Sterility2025-06-192 citations

Pain Reduction in Linzagolix‐Treated Patients With Uterine Fibroids: A Secondary Mediation Analysis of the <scp>PRIMROSE</scp> 1 and 2 Phase 3 Trials

BJOG An International Journal of Obstetrics & Gynaecology2025-05-062 citations

Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.

2022-09-0143 citations

O-135 Long term secondary efficacy of linzagolix for heavy menstrual bleeding (HMB) due to uterine fibroids (UF): 52-week results from two placebo-controlled, randomized, phase 3 trials

Human Reproduction2021-07-011 citations